Treatment for Pulmonary Arterial Hypertension Cleared PDF Print E-mail
Thursday, 17 September 2009 14:50
taken from http://www.flickr.com/photos/dhedwards/383835919/Renal & Urology News has recently reported in its September Issue that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to increase walk distance in patients with New York Heart Association Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with Scleroderma and congenital heart disease.

In the TRIUMPH-1 randomized, double-blind, 12-week, placebo-controlled clinical trial, patients taking treprostinil in four daily inhalation sessions achieved a 20-meter improvement in six-minute walk distance compared with placebo recipients. The safety and effectiveness in patients with underlying lung disease has not been established. The most common side effects seen with treprostinil were cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, and diarrhea.
 
More articles :

» African Americans Have More Severe Complications From Scleroderma

African Americans have more severe complications from systemic sclerosis, also known as scleroderma, than Caucasians. Findings published today in, , a journal of the American College of Rheumatology (ACR), show that compared with Caucasians,...

» Survival In Pulmonary Hypertension

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisARTHRITIS & RHEUMATISMVol. 60, No. 2, February 2009, pp 569–577 DOI 10.1002/art.24267 © 2009, American College of...

» Clinical Manifestations of Heart Disease In Autoimmune Disorders

Dr. Lawrence Phillips is the Assistant Professor of Medicine, Division of Cardiology and Director of Nuclear Cardiology at the . At the recently concluded , Dr. Phillips presented on the clinical manifestations of heart diseases in autoimmune...

» Methotrexate Effective In Juvenile Localized Scleroderma

is effective in when given with a short course of steroids, an Italian randomized study confirmed.Among children ages 6 to 17 receiving methotrexate, 67.4% completed the yearlong trial without flaring, compared with 29.2% of those given placebo...

» UC Davis Researchers Win Prestigious NIH Awards

The National Institutes of Health on Tuesday named three UC Davis researchers recipients of highly competitive awards designed to encourage innovative, high-risk research and accelerate the translation of science into improved health.Reflecting the...

» Systemic Sclerosis Patients Treated With Oral Treprostinil Diethanolamine

Patients with effectively absorbed oral treprostinil diethanolamine, which produced a temporal association with improved cutaneous perfusion and temperature, according to study results. In a dual-center, open-label, phase 1 study, researchers...